Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin
| Autor: | Mariagrazia Granata, Maurizio Pettinato, Maria Clorinda Mazzarino, Fabio D’Amico, Chiara Trovato, Giulio A. Rossi, Pietro Gangemi, Evangelia Skarmoutsou, Valentina Longo |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male S100A7 Inflammation Dermatology Biochemistry S100 Calcium Binding Protein A7 IL-12/-23p40 Etanercept Young Adult Psoriasis Ustekinumab medicine Adalimumab Humans Biological therapy skin and connective tissue diseases Molecular Biology Aged Skin Psoriasin integumentary system business.industry S100 Proteins Middle Aged medicine.disease Immunohistochemistry Immunology Female Tumor necrosis factor alpha medicine.symptom business medicine.drug |
| Zdroj: | Journal of Dermatological Science. 80:38-44 |
| ISSN: | 0923-1811 |
| DOI: | 10.1016/j.jdermsci.2015.07.009 |
| Popis: | Background Psoriasis is a chronic inflammatory skin disease. It is characterized by immune cell activation and altered epidermal differentiation. S100A7 (psoriasin) is overexpressed in psoriasis, suggesting a determinant role of this protein in inflammation and keratinocyte differentiation. Objective The purpose of this study was to investigate the expression of S100A7 in the skin from psoriatic patients undergoing biological therapy with adalimumab, etanercept or ustekinumab. Methods S100A7 expression and distribution were analyzed by immunohistochemistry. Results S100A7, overexpressed in epidermal keratinocytes of psoriatic lesions, was downregulated, under the biological therapy with adalimumab, etanercept or ustekinumab, only in patients achieving a PASI score Conclusions Dysregulation of S100A7 may represent a non-negligible player in the maintenance of psoriasis and the relative epidermal changes. Blockage of S100A7 may represent an additional therapeutic approach in the treatment of psoriasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect